# Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970

> **NCT04907149** · PHASE1 · COMPLETED · sponsor: **Lakefront Biotherapeutics NV** · enrollment: 6 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** GLPG3970 film-coated tablet
- **DRUG:** [14C]GLPG3970 solution for infusion
- **DRUG:** [14]GLPG3970 oral solution

## Key facts

- **NCT ID:** NCT04907149
- **Lead sponsor:** Lakefront Biotherapeutics NV
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-06-07
- **Primary completion:** 2021-07-12
- **Final completion:** 2021-07-12
- **Target enrollment:** 6 (ACTUAL)
- **Last updated:** 2021-07-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04907149

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04907149, "Evaluation of Mass Balance and Absolute Bioavailability of GLPG3970". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04907149. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*